Literature DB >> 31463099

Evaluation of a novel collagen hemostatic matrix in a porcine heart and cardiac vessel injury model.

Heemoon Lee1,2, Jun Ho Lee2,3, Chang-Seok Jeon2, Jae Hyung Ko4, Si-Nae Park4, Young Tak Lee2.   

Abstract

BACKGROUND: Flowable hemostatic agents may be more advantageous than nonflowable hemostats, as they have capability to cover irregular wound surfaces, fill deep lesions, and easily remove excess materials with irrigation. In this study, we evaluated the hemostatic efficacy of the collagen hemostatic matrix (CHM) compared to FloSeal® via incisions in the heart and cardiac vessels in a porcine model.
METHODS: In each of the two female pigs, a total of two incisions were made in seven locations: right atrium (RA), right ventricle (RV), and cardiac vessels, such as the innominate vein (IV), superior vena cava (SVC), pulmonary artery (PA), coronary artery (CA), and aorta. Hemostatic agents were applied directly to the bleeding wounds. In certain location, one incision was treated with the CHM and the other with FloSeal®, and the time to hemostasis and the degree of bleeding of the two agents were assessed and compared. One week after surgery, the animals were sacrificed, and specimens were collected for histologic evaluation.
RESULTS: Bleeding from the vessels with relatively low pressure (the IV, SVC, and RA) was controlled within 1-2 minutes using both a CHM and FloSeal®. Bleeding from the vessels with high blood pressure (the RV, PA, CA, and aorta) was controlled within 3-10 minutes with the CHM. However, hemostasis in the PA and CA was not achieved with FloSeal®. Histological analysis revealed that the use of both the CHM and FloSeal® resulted in foreign body reactions of similar severity.
CONCLUSIONS: The hemostatic effect and safety of the CHM may be similar to that of FloSeal®. Further clinical studies must be conducted to validate our results.

Entities:  

Keywords:  Collagen; hemostatics; swine; thoracic surgery; thrombin

Year:  2019        PMID: 31463099      PMCID: PMC6688000          DOI: 10.21037/jtd.2019.06.59

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  7 in total

1.  Evaluation of the safety and efficacy of a new hemostatic powder using a quantitative surface bleeding severity scale.

Authors:  Abbas Ardehali; William D Spotnitz; Rachel W Hoffman; Steven A Olson; Grant V Bochicchio; Mark C Hermann; Shankar Lakshman; Nick C Dang; Valerie Centis; Dan L Gillen; Ian J Schorn; Russell H Spotnitz
Journal:  J Card Surg       Date:  2019-01-10       Impact factor: 1.620

2.  An Experimental Study of Histopathologic Effects of Hemostatic Agents Used in Spinal Surgery.

Authors:  Idiris Altun
Journal:  World Neurosurg       Date:  2016-02-18       Impact factor: 2.104

3.  Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group.

Authors:  M C Oz; D M Cosgrove; B R Badduke; J D Hill; M R Flannery; R Palumbo; N Topic
Journal:  Ann Thorac Surg       Date:  2000-05       Impact factor: 4.330

4.  Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery.

Authors:  Giuseppe Nasso; Felice Piancone; Raffaele Bonifazi; Vito Romano; Giuseppe Visicchio; Carlo Maria De Filippo; Barbara Impiombato; Flavio Fiore; Francesco Bartolomucci; Francesco Alessandrini; Giuseppe Speziale
Journal:  Ann Thorac Surg       Date:  2009-11       Impact factor: 4.330

Review 5.  Comparison of hemostatic agents used in vascular surgery.

Authors:  Krishna S Vyas; Sibu P Saha
Journal:  Expert Opin Biol Ther       Date:  2013-10-22       Impact factor: 4.388

Review 6.  Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review.

Authors:  María Echave; Itziar Oyagüez; Miguel Angel Casado
Journal:  BMC Surg       Date:  2014-12-20       Impact factor: 2.102

7.  Comparison of two gelatin and thrombin combination hemostats in a porcine liver abrasion model.

Authors:  Kevin M Lewis; Holly D Atlee; Angela J Mannone; Joseph Dwyer; Lawrence Lin; Andreas Goppelt; Heinz Redl
Journal:  J Invest Surg       Date:  2013-03-20       Impact factor: 2.533

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.